Community Health Media
  • Home
  • What We Do
  • Playlists
  • Content Library
    • HER2+
    • HR+
    • HER2-Low / Ultra-Low
    • Triple Negative
    • High Risk
  • Podcasts
    • Breast Friends
    • Apple Podcasts
    • Spotify
    • Amazon Music
    • iHeartRadio
    • Castbox
    • Goodpods
    • Pocket Casts
  • Contact Us
  • ···
        • Youtube
        • Facebook
        • LinkedIn
        • Instagram
    Community Health Media
    • Home
    • What We Do
    • Playlists
    • Content Library
      • HER2+
      • HR+
      • HER2-Low / Ultra-Low
      • Triple Negative
      • High Risk
    • Podcasts
      • Breast Friends
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • iHeartRadio
      • Castbox
      • Goodpods
      • Pocket Casts
    • Contact Us
    • ···
          • Youtube
          • Facebook
          • LinkedIn
          • Instagram
      Community Health Media
      • Home
      • What We Do
      • Playlists
      • Content Library
        • HER2+
        • HR+
        • HER2-Low / Ultra-Low
        • Triple Negative
        • High Risk
      • Podcasts
        • Breast Friends
        • Apple Podcasts
        • Spotify
        • Amazon Music
        • iHeartRadio
        • Castbox
        • Goodpods
        • Pocket Casts
      • Contact Us

      How Long Do You Stay on T-DXd in mBC? The Hardest Question

      Maximum response, maintenance therapy, or continuing until toxicity?

      This candid discussion highlights how clinicians balance efficacy, resistance, and patient goals when deciding how long to stay on T-DXd.

      FacebookXRedditPinterestEmail

      You may also like

      Video

      Rethinking First-Line Metastatic HER2+ Therapy with T-DXd – Drs. Mouabbi, O’Shaughnessy & Rimawi

      1 min read
      Video

      40-Month PFS: Can T-DXd Move to the Frontline?

      1 min read
      Video

      If T-DXd is Working, Do You Ever Stop?

      1 min read
      Video

      PIK3CA Mutations: The Hidden Resistance Pathway in HER2+ Disease

      1 min read
      Video

      Managing ILD & Nausea on T-DXd: What Actually Works

      1 min read

      Recommended Videos

      Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea

      4 months ago

      Has HER2+ First-Line Treatment Officially Changed? – Dr. Neil Iyengar & Dr. Martin Dietrich

      4 months ago

      New First-Line Strategies in HER2+ Metastatic Breast Cancer – Dr. Mark Pegram & Dr. Carol Tweed

      4 months ago

      Cleopatra, DESTINY-Breast09 & What Comes Next – Drs. Bill Gradishar, Tarah Ballinger, & Megan Kruse

      4 months ago

      Community Health Ventures

      Address:

      2471 18th St NW
      Second Floor
      Washington, DC 20009

      Email: info@communityhealth.media

      Follow Us

      • youtube
      • facebook
      • linkedin
      • instagram

      Quick Links

      • About
      • KOL Playlists
      • Contact Us
      • Privacy Policy
      • Terms of Use

      Content By Topics

      • HER2+
      • HR+
      • Triple Negative
      • HER2-Low / Ultra-Low
      • High Risk

      Podcast Network

      • Breast Friends Podcast
      • Apple Podcasts
      • Spotify
      • Amazon Music
      • Castbox
      • Goodpods
      • iHeartRadio
      • Pocket Casts
      © 2026 Community Health Technologies, Inc. All Rights Reserved